Oritavancin (MIC 50/90 , 0.03/0.06 to 0.12 g/ml) had potent activity against linezolid-resistant staphylococci, as well as Enterococcus faecalis and Enterococcus faecium (oritavancin MIC 50/90 , 0.015/0.12 g/ml against both species). All linezolid-resistant isolates were inhibited by oritavancin at <0.12 g/ml. These results confirmed the absence of cross-resistance between linezolid and oritavancin in staphylococci and enterococci.
S taphylococcus aureus (including methicillin-resistant S. aureus
[MRSA]), coagulase-negative staphylococci (CoNS), Enterococcus faecium, and multidrug-resistant (MDR) streptococci are frequently isolated pathogens responsible for various clinical infections (1) . Several national and local studies have documented a decrease in the incidence of invasive MRSA infections in the United States (2) (3) (4) . However, MRSA is still estimated to cause ϳ80,000 invasive infections and result in 11,000 deaths annually in the United States (5) . Vancomycin-resistant enterococci (VRE) are estimated to cause 20,000 hospital-acquired infections and 1,300 deaths each year (5) . Moreover, MRSA and E. faecium are among the defined ESKAPE organisms (E. faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.), which cause the majority of U.S. nosocomial infections and are often refractory to many clinically available agents (6) .
Linezolid is an anti-Gram-positive agent approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) (7), with potent activity against clinical pathogens causing infections worldwide according to large surveillance studies (8, 9) . Although uncommon, linezolid resistance does occur, especially after prolonged administration (7, 10) , and local investigations have reported occurrences of sporadic outbreaks (11) (12) (13) (14) and dissemination of linezolid-dependent isolates (15, 16) . Alterations in linezolid binding sites (23S rRNA and L3 and L4 ribosomal proteins) remain the most common mechanisms of oxazolidinone resistance (7) . Additionally, transferrable resistance determinants, such as cfr, cfr(B), and optrA, represent newer mechanisms responsible for decreased susceptibility to linezolid (17) (18) (19) . This study was conducted to evaluate the in vitro activity of oritavancin, a recently approved lipoglycopeptide for the treatment of ABSSSI (20) , against a molecularly characterized collection of isolates displaying elevated linezolid MIC results.
A total of 25 S. aureus (linezolid MIC range, 4 to 32 g/ml), 80 CoNS (linezolid MIC range, 4 to Ͼ128 g/ml), and 45 enterococci (linezolid MIC range, 4 to 64 g/ml) were included (see Table S1 in the supplemental material). These isolates were selected based on the presence of linezolid resistance mechanisms, although some staphylococcal isolates showed a linezolid MIC result (4 g/ ml) at the breakpoint for susceptibility (i.e., Յ4 g/ml) (21). Isolates were recovered from a network of medical centers as part of the SENTRY Antimicrobial Surveillance Program and submitted Table S1 in the supplemental material). Oritavancin had modal MIC, MIC 50 , and MIC 90 results of 0.03, 0.03, and 0.06 g/ml, respectively, against S. aureus, displaying elevated MIC values for linezolid (Table 1). Similar results were observed for oritavancin against Cfrproducing S. aureus. The MIC 50 result for oritavancin (MIC 50/90 , 0.03/0.06 g/ml) was 8-and 32-fold lower than those for daptomycin (MIC 50/90 , 0.25/0.5 g/ml) and vancomycin (MIC 50/90 , 1/2 g/ml), respectively, against all S. aureus isolates, including those carrying cfr (Table 2) .
CoNS (linezolid MIC 50/90 , 32/128 g/ml) showed a diverse array of linezolid resistance mechanisms and the highest linezolid MIC results observed among pathogens included in this study (Table 1; see also Table S1 in the supplemental material). Although often considered contaminants, CoNS isolates are also recognized as increasingly important causes of bloodstream and medical device-related infections in hospitalized patients (24) . The majority of nosocomial CoNS isolates belong to clonal complex 2 (25) (26) (27) , and some isolates associated with this lineage have demonstrated linezolid dependence (15, 16) . Moreover, the linezolid resistance mechanisms observed among CoNS isolates have evolved considerably over time and become more complex (7) . In this study, oritavancin (MIC 50/90 , 0.03/0.12 g/ml) inhibited all CoNS isolates at Յ0.12 g/ml and had MIC values that were 4-to 16-fold lower than those of daptomycin (MIC 50/90 , 0.5/0.5 g/ml) and 16-to 128-fold lower than those of vancomycin (MIC 50/90 , 2/2 g/ml) or teicoplanin (MIC 50/90 , 4/8 g/ml) ( Table 2) .
The majority of linezolid-nonsusceptible enterococci showed the G2576T alteration in 23S rRNA, and three isolates (6.7%) had a concomitant presence of cfr. Two E. faecium and seven E. faecalis isolates had the recently described cfr(B) variant and optrA ABC transporter, respectively (see Table S1 in the supplemental material). A total of 15.4% and 75.0% of linezolid-nonsusceptible E. faecalis and E. faecium, respectively, were vancomycin resistant (all VanA phenotype) ( Tables 1 and 2 ). Oritavancin (MIC 50/90 , 0.015/0.12 g/ml) inhibited all enterococcal isolates at Յ0.12 g/ ml, except for one isolate of E. faecalis (MIC, 1 g/ml) ( Tables 1  and 2 ). Oritavancin (MIC 50/90 , 0.015/0.12 g/ml), ampicillin (MIC 50/90 , Յ1/2 g/ml), and daptomycin (MIC 50/90 , 1/2 g/ml) were active against E. faecalis, and oritavancin (MIC 50/90 , 0.015/ 0.12 g/ml) and daptomycin (MIC 50/90 , 2/2 g/ml) were also active against E. faecium (Table 2) .
Oritavancin became clinically available in the United States and Europe as a single-dose treatment for ABSSSIs (20) . The results obtained herein document potent in vitro activity of oritavancin against a collection of Gram-positive pathogens with elevated linezolid MICs, regardless of the linezolid resistance mechanism. Overall, oritavancin inhibited all tested isolates at Յ0.12 g/ml (except for one isolate of vancomycin-resistant E. faecalis; MIC, 1 g/ml), including isolates expressing newly characterized and transferable (plasmid-encoded) linezolid resistance mechanisms. The absence of in vitro cross-resistance between linezolid and oritavancin as documented in this study is likely to be based on the distinct mechanisms of action of these two agents (29, 30) .
